Literature DB >> 4091993

Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.

P N Shaw, J B Houston, M Rowland, K Hopkins, J F Thiercelin, P L Morselli.   

Abstract

Antipyrine total clearance and the formation clearance of its major metabolites were studied in normal, healthy male volunteers before and after multiple dosing for approximately three weeks with phenytoin (six subjects) and carbamazepine (six subjects). Total antipyrine clearance increased on average by 91% after phenytoin dosing and by 61% after carbamazepine and individual increases correlated well with mean plasma concentrations of the anti-epileptic drug. The increase in total clearance resulted largely from increased formation clearances of the 4-hydroxy and 3-hydroxymethylantipyrine metabolites with minimal effect on the norantipyrine pathway, following treatment with both enzyme-inducing drugs. It is concluded that both phenytoin and carbamazepine have similar effects on antipyrine metabolism and that these effects are mediated by induction of specific forms of cytochrome P450.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4091993      PMCID: PMC1400829          DOI: 10.1111/j.1365-2125.1985.tb05119.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  The fate of antipyrine in man.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

3.  Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors:  C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

4.  Urinary D-glucaric acid excretion and acetanilide pharmacokinetics before and during diphenylhydantoin administration.

Authors:  J L Cunningham; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Metabolism of drugs. LIX. A new metabolite of antipyrine.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1968-08       Impact factor: 5.858

6.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

7.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Authors:  M Danhof; D P Krom; D D Breimer
Journal:  Xenobiotica       Date:  1979-11       Impact factor: 1.908

9.  Quantitation and urinary pattern of 4,4'-dihydroxy-antipyrine, 4-hydroxy-antipyrine and 3-hydroxymethyl-antipyrine, as main metabolites of antipyrine in man and rat.

Authors:  J Böttcher; H Bässmann; R Schüppel
Journal:  J Pharm Pharmacol       Date:  1982-03       Impact factor: 3.765

10.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  10 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  A comparative review of the adverse effects of anticonvulsants in children with epilepsy.

Authors:  S J Wallace
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

6.  Theophylline and antipyrine disposition in smoking and non-smoking epileptic subjects.

Authors:  D W Acheson; S Uden; J M Braganza; S W Brown; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

7.  Comparison of trimethadione and antipyrine as indicators of oxidative drug metabolizing capacity in man.

Authors:  E Tanaka; K Nakamura
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 9.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Authors:  M Strolin Benedetti; P Dostert
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

10.  Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.

Authors:  Daniel Scotcher; Christopher Jones; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  Eur J Pharm Sci       Date:  2016-03-28       Impact factor: 4.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.